CD274 and neoplasm: It is speculated that tumors with higher mutation burden have more tumor-specific neoantigens, which stimulate the increase in the number of TILs caused by the overexpression offset of immune checkpoint modulators, such as the programmed death receptor 1 (PD-1) or programmed cell death ligand 1 (PD-L1) (35–38).